Characterization of a sesquiterpene synthase and a short-chain dehydrogenase in zerumbone biosynthesis and the applications in engineered Saccharomyces cerevisiae
- PMID: 41114138
- PMCID: PMC12532338
- DOI: 10.3389/fpls.2025.1635141
Characterization of a sesquiterpene synthase and a short-chain dehydrogenase in zerumbone biosynthesis and the applications in engineered Saccharomyces cerevisiae
Abstract
Introduction: Zerumbone is a pharmacologically active sesquiterpenoid with limited availability. This study aims to elucidate its biosynthetic pathway in Curcuma wenyujin by identifying and characterizing the key enzymes responsible for its production.
Methods: Candidate genes were selected via transcriptome analysis and phylogenetics. CwTPS8 and CwSDR1 were cloned and functionally characterized using in vitro enzyme assays and heterologous expression in engineered Saccharomyces cerevisiae. Molecular docking and site-directed mutagenesis were applied to investigate the catalytic mechanism of CwTPS8.
Results: CwTPS8 was identified as a multifunctional sesquiterpene synthase that catalyzes the formation of α-humulene (a key zerumbone precursor) and β-caryophyllene as main products, along with several minor sesquiterpenes. Mutagenesis studies identified critical residues (e.g., Thr437, Cys436) that significantly shift product specificity toward α-humulene. CwSDR1 was characterized as a short-chain dehydrogenase that efficiently oxidizes 8-hydroxy-α-humulene to zerumbone. A de novo biosynthetic pathway was reconstructed in yeast, resulting in zerumbone production at 0.50 μg/L.
Discussion: This study expands the genetic toolkit for zerumbone biosynthesis and provides insights into enzyme engineering and metabolic engineering strategies to enhance production. Limitations in precursor supply and catalytic efficiency highlight areas for future optimization.
Keywords: Curcuma wenyujin; sesquiterpene synthase; short-chain dehydrogenase; zerumbone; α-humulene.
Copyright © 2025 Xu, Xia, Fang, Li, Ma, Li, Wei, Tu, Yin and Hu.
Conflict of interest statement
Authors QW and TH were employed by the company Zhejiang Medicine Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                References
- 
    - Alsaffar R. M., Ali A., Rashid S. M., Ahmad S. B., Alkholifi F. K., Kawoosa M. S., et al. (2023). Zerumbone protects rats from collagen-induced arthritis by inhibiting oxidative outbursts and inflammatory cytokine levels. ACS Omega 8, 2982–2991. doi: 10.1021/acsomega.2c05749, PMID: - DOI - PMC - PubMed
 
LinkOut - more resources
- Full Text Sources
 
        